Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the growth stocks that could double by 2027. On July 14, CORT submitted an FDA application for relacorilant to treat platinum-resistant ovarian cancer, based on promising Phase 2 and 3 trial data.

Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant

A professional scientist in a laboratory, visually demonstrating the development of Microbiome therapeutics platform.

Patients receiving the drug with nab-paclitaxel experienced notable improvements in survival outcomes without added safety risks. With relacorilant already designated as an orphan drug and a decision date set for December 30, 2025, this milestone marks Corcept’s second active NDA submission.

Relacorilant modulates cortisol activity via glucocorticoid receptors and has shown strong clinical potential. Backed by robust financials, including a 128% stock return over the past year and a current ratio of 3.07, Corcept is well-positioned to target the estimated 20,000 U.S. patients needing new therapies for platinum-resistant disease annually. If approved, this drug could significantly enhance treatment options and expand the company’s oncology portfolio.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharma firm specializing in therapies that regulate cortisol, a key hormone in body function. Its lead product, Korlym, is FDA-approved for treating Cushing’s syndrome, a condition caused by excess cortisol.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.